Onesource Specialty Pharma Limited has disclosed that one of its promoter entities has pledged a significant portion of equity shares to meet business requirements. The pharmaceutical company made this announcement through a regulatory filing dated December 18, 2025.

Share Pledge Details

Tenshi Pharmaceuticals Private Limited pledged 20,00,000 equity shares of Onesource Specialty Pharma Limited on December 16, 2025. The pledge was executed to address certain business and operational needs of the promoter entity.

Regulatory Compliance

The disclosure was made in compliance with Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The company submitted the required Form to both the Bombay Stock Exchange and National Stock Exchange of India.

The filing was signed by Pudhuccode Radhakrishnan Kannan, Director of Tenshi Pharmaceuticals Private Limited, with DIN 03435209.

Company Information

Onesource Specialty Pharma Limited operates in the pharmaceuticals sector with its registered office located in Navi Mumbai, Maharashtra. The company's corporate office is situated in Bangalore, Karnataka.

Tenshi Pharmaceuticals Private Limited, the pledging entity, has its registered office in Bengaluru, Karnataka. The entity operates under CIN: U74999KA2016PTC200180.

This pledge transaction represents a corporate action undertaken by the promoter group to meet specific business requirements while maintaining regulatory compliance and transparency with market participants.

Onesource Specialty Pharma , a prominent player in the pharmaceutical industry, has announced its decision to withdraw from the upcoming Jefferies Global Healthcare Conference. The event, scheduled for November 18-20, 2025, in London, is a significant platform for healthcare companies to engage with investors and industry peers.

Reason for Withdrawal

The company cited "urgent matters" as the primary reason for their absence from the conference. This unexpected development has raised questions about the nature of these urgent matters and their potential impact on the company's operations.

Impact on Investor Relations

The Jefferies Global Healthcare Conference is known for providing valuable opportunities for companies to:

• Present their business strategies
• Showcase recent developments
• Engage with potential investors

ONESource Specialty Pharma's absence from this event may affect its planned interactions with investors and industry analysts.

Official Communication

ONESource Specialty Pharma officially communicated its decision to withdraw from the conference. The company's Company Secretary and Compliance Officer, Trisha A, signed the official notice, which was submitted to regulatory authorities.

Company Background

ONESource Specialty Pharma Limited, formerly known as Stelis Biopharma Limited, is headquartered in Bengaluru, India. The company operates in the specialty pharmaceutical sector, focusing on developing and manufacturing pharmaceutical products.

Investors and industry observers will likely be watching closely for any further announcements or developments from ONESource Specialty Pharma in the coming days.